In October 2022, PROVIREX announced a major expansion in Hamburg’s .
The core of Hamburg’s research is , developed through directed molecular evolution by teams led by Prof. Joachim Hauber. In October 2022, PROVIREX announced a major expansion
Preclinical data showed the enzyme has no measurable cytotoxic or genotoxic side effects, making it a viable candidate for human testing. 3. 2022 Milestones: The Hamburg Therapy Hub In October 2022